Brian Van Tine, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Acuta Capital Partners, LLC
    Topic:
    Consulting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Aadi
    Topic:
    Consulting/ Attended an advisory board meeting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Race Oncology
    Topic:
    Consulting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Hinge Bio
    Topic:
    Consulting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Kronos Bio
    Topic:
    Consulting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Kronos Bio
    Topic:
    Travel to meeting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Iterion Therapeutics, Inc.
    Topic:
    Consulting
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Total Health Conference
    Topic:
    Educational Talk
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Total Health Conference
    Topic:
    Travel to speak at conference.
    Date added:
    08/11/2023
    Date updated:
    08/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Adaptimmune
    Topic:
    Travel to speak at Conference
    Date added:
    08/11/2023
    Date updated:
    08/11/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond